Drugs for Alzheimer's disease and related dementias

British Medical Journal

Volumn 330, Issue 7496, 2005, Pages 857-858

  Gauthier, Serge ^a,b  

^a Dept Ophthalmol Neurol N   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; CARBAMIC ACID DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE;

AGITATION; ALZHEIMER DISEASE; ANXIETY; APATHY; CAREGIVER; COGNITION; DEMENTIA; DEPRESSION; DRUG EFFICACY; EDITORIAL; HUMAN; NURSING HOME; PARKINSON DISEASE; PRIORITY JOURNAL; NOTE; PRACTICE GUIDELINE; TREATMENT WITHDRAWAL;

ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; DEMENTIA; DIBENZOTHIAZEPINES; HUMANS; PHENYLCARBAMATES; PRACTICE GUIDELINES; WITHHOLDING TREATMENT;

EID: 17244380003     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.330.7496.857     Document Type: Editorial

References (10)

1. Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 2005; 330:874-7.
2. Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatria 2002;14:389-404.
3. Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001;49:1590-9.
4. Aalten P, de Vugt ME, Lousberg R, Korten E, Jaspers N, Senden B, et al. Behavior problems in dementia: as factor analysis of the neuropsychiatric inventory. Dement Geriatr Cogn Disord 2003;15:99-105.
5. Cohen-Mansfield J, Libin A. Assessment of agitation in elderly patients with dementia: correlations between informant rating and direct observation. Int J Geriatr Psychiatry 2004;19:881-91.
6. Senanarong V, Cummings JL, Fairbanks L, Mega M, Masterman DM, O'Connor SM, et al. Agitation in Alzheimer's disease is a manifestation of frontal lobe dysfunction. Dement Geriatr Cogn Disord 2004;17:14-20.
7. Profenno LA, Tariot PN. Pharmacologic management of agitation in Alzheimer's disease. Dement Geriat Cogn Disord 2004;17:65-77.
8. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-18.
9. Juncos JL, Roberts VJ, Evatt ML, Jewart RD, Wood CD, Poiter LS, et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Movement Disorders 2003;19:29-35.
10. National Institute for Health and Clinical Excellence (NICE). Appraisal consultation document: Alzheimer's disease-donepezil, rivastigmine, galantamine and memantine (review). www.nice.org.uk/page.aspx?o = 245912 (accessed 11 Apr 2005).